ZyVersa Therapeutics Overview
Valuation check: ZVSA's ROE is 173.38%, above the sector sector average of -5.72%.
Get informed when a big investor buys or sells
+ Follow173.38%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
ZyVersa Therapeutics (ZVSA) currently reports a ROE of 173.38%. That is above the sector sector average of -5.72%. Use the charts on this page to explore ZyVersa Therapeutics's ROE history and peer comparisons.
ZyVersa Therapeutics's ROE of 173.38% is higher than the its sector sector average of -5.72%. That is roughly 3129.9% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' ROE, but ZyVersa Therapeutics's current 173.38% should be judged against industry norms (sector average: -5.72%) and against ZVSA's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current ROE of 173.38%, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is -5.72%. From there, open related valuation or income-statement pages for ZyVersa Therapeutics, and consider following ZVSA for alerts when major investors trade the stock.
